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Vena caval filters are placed routinely in the
infrarenal portion of the inferior vena cava (IVC).
However, in certain situations, it is advisable to posi-
tion the device above the level of the renal veins.
Such placement correctly raises questions regarding
the potential for complications, such as caudal
migration, caudal slippage of a filter limb into a renal
or a tributary vein, and obstruction of the cava and
the renal veins from occlusion of the filter.
In prior reports, we summarized our experience
after suprarenal (SR) placement of the Greenfield
vena caval filter in 12 and in 69 patients.1,2 These
earlier studies had small sample sizes but indicated
no renal impairment. Both efficacy and safety were
comparable with patients with infrarenal filters. The
purpose of the current review is to determine whether
a larger and a longer experience with different models
of the filter is consistent with the earlier reports and
whether any adverse events develop in time. 
METHODS
All patients who undergo filter placement at the
University of Michigan Medical Center are asked to
return for routine follow-up, which includes color-
flow duplex scan of the IVC, lower extremities, and
anteroposterior and lateral abdominal radiographs.
In addition, the patients are questioned about addi-
tional hospitalizations and the use of anticoagulation
therapy. They are evaluated for the presence of
lower-extremity edema or ulceration and for the
need for support hose. Those patients who are
symptomatic with bilateral edema and absent
Doppler signals may undergo further diagnostic
testing to confirm caval occlusion and blood chem-
istry studies to evaluate renal function. Those
patients with a significant change in filter base diam-
eter (>7 mm) may undergo computed tomographic
scanning to determine whether there is penetration
of adjacent tissues. 
Data from annual follow-up visits have been col-
lected since 1972 from the University of Oklahoma
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for Health Sciences, from the Medical College of
Virginia (1974-1987), and from the University of
Michigan (1987-1997). These data were entered
into the Greenfield Filter Database maintained at the
University of Michigan. Statistical analyses were per-
formed with Systat 5.2 (SYSTAT, Evanston, Ill) for
the Macintosh. The Kruskal-Wallis nonparametric
test for analysis of variance, the Mann-Whitney U
test, or the t test were used for continuous data, and
the Fisher exact test or the c 2-test were used for
dichotomous data.
RESULTS
Filters were placed above the renal veins in 148
of 1932 cases (7.6%), and 73 cases (49%) had fol-
low-up. The studies included 91 women and 57
men, with a mean age of 46 years. Table I charac-
terizes patients with SR filters as compared with
those with infrarenal placement. Seventy-eight
patients are alive; 61 have had at least 1 follow-up,
and 14 will be due for their first follow-up during
the next 12 months. Fifty-two patients are dead—24
of them within 30 days of filter placement, with
malignant disease being the primary diagnosis in 18.
Ten of the patients had follow-up before death.
Patients not responding to notices for 5 or more
years are considered lost to follow-up. Of these 18
patients, 7 have had at least 1 follow-up examina-
tion. The rate of SR-filter recurrent pulmonary
embolism (PE) was 8% (6/73) as opposed to 4% for
infrarenal placement, which was not statistically sig-
nificant (Fig. 1). Recurrent PE was the indication for
SR filter placement in 5 of the 6 cases. Of the 4
patients with initial caval occlusion, 2 had a con-
traindication to anticoagulation therapy and the
other 2 had filters placed after a previous PE. Vena
caval patency rate initially was 95% but increased to
97.3% for the long-term period when 2 patients
were noted to have recanalized cavas at subsequent
examinations. No evidence of acute or chronic renal
dysfunction was seen among those patients with
caval occlusion on the basis of changes in laboratory
test results. Complication rates were not statistically
different from those of patients with filters in other
positions. Survival time reflects the number of
months from the time of filter placement until the
last actual contact with the patient. The mean sur-
vival time was 56 months (range, 0 to 278 months),
which is slightly longer than in the infrarenal group
(53 months). The average number of follow-up
examinations was 1 (range, 0 to 16). Survival rate
was shown to be associated significantly with the
Fig. 1. Patient with recurrent PE after SR filter. A large
thrombus can be noted in the filter. A second filter was
placed, and patient is doing well 5 years later.
Table I. Characteristics of patients with suprarenal
vena caval filters compared with those of patients
with infrarenal filters
SR IR
(n = 148) (n = 1784)
Percent of placements 7.6% 92.4%
Male gender 9% 54%
Age (mean) 48 years 54 years
Percent with follow-up 49% 42%
Primary diagnosis
Malignant disease 29% 19%
Surgery 16% 24%
Mortality rate (all causes) 35% 52%
Recurrent PE 8% 3.7%
Caval occlusion 5% 4%
Primary indication
Contraindication to anticoagu- 31% 38%
lation therapy
Prophylaxis 31% 33%
Thromboembolism in 64%
No thromboembolism in 36%
Survival time 56 months 53 months
SR, Suprarenal; IR, infrarenal; PE, pulmonary embolism.
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Fig. 2. Patients with primary diagnosis of malignant diseases or pulmonary disorders have the short-
est survival periods.
Fig. 3. Although 83% of patients with failure of suprarenal filter had recurrent PE as primary indication for
placement, the failure did not adversely affect survival rate.
underlying diagnosis (P = .003; test statistic = 24.6,
with 9 degrees of freedom [df]) and the indication
(P = .038; Kruskal-Wallis test statistic = 11.76, with
5 df) at the time of placement (Figs. 2 and 3).
Despite a 36-month survival rate advantage
among those patients with recurrent PE, we were
unable to show a statistical association between sur-
vival rate and recurrent PE (P = .2; t test, with t =
1.293, 70 df). Most filters were placed by radiologists
with a percutaneous technique through the right
jugular vein (36%). SR placement resulted from prior
filter misplacement in 6 cases (4%; Fig. 4). In 19
cases, the SR filter was placed because of a problem
with an infrarenal filter, such as extension of throm-
bus or recurrent PE (Fig. 5). The remainder were
placed intentionally at this level in female patients of
child-bearing potential and in those patients with
extensive thrombus in the IVC. Most filters were
original stainless-steel (SGF; 43%), followed closely
by the titanium filter (41%; Table II). Table III sum-
marizes the status of the 148 patients with SR filters.
Follow-up data are available for 73 patients (49%;
Table IV) for periods ranging from 0 to 278 months
(mean, 81.6 months). Anticoagulation therapy was
required by 48% at some time in the postplacement
period. Evidence of chronic venous insufficiency was
found in the 29 patients who required compression
stockings to control edema. Four patients had at least
1 episode of venous stasis ulceration. Lower-extrem-
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Fig. 4. Original stainless-steel filter misplaced into renal vein.
Fig. 5. Two limbs of this infrarenal SGF slipped into iliac
vein. TGF was placed in suprarenal vena cava. 
ity studies in 72 of 73 patients with follow-up
showed stable or improved venous status with only 1
new abnormality. There were 6 patients with sus-
pected or proven recurrent PE (8%); no case was
fatal. Penetration of the vena cava was suspected in 4
cases but confirmed by means of computed tomog-
raphy in only 1. All movement was caudal, occurring
in 11 cases and ranging from 2 to 80 mm. The mean
migration distance was 3 times greater for male
patients than for female patients (7 vs 2 mm).
Fracture of a stainless-steel filter strut occurred in 3
cases, but all have remained asymptomatic. The
devices remain unchanged over time with no sequelae
(Fig. 6). When the filter was placed above the renal
vein simply because the female patient was of child-
bearing potential (30 cases), outcomes were signifi-
cantly better. No cases of PE were seen, and the only
caval thrombosis had cleared within the first year.
The group of patients who experienced recurrent
PE despite an SR filter requires further analysis. This
group was 4 years younger on average. There were
twice as many male patients (3/25) as female
patients (3/48), and there was a 2-fold difference in
caudal migration (8.6 vs 3.5 mm). The failure rate
for the original SGF was 4/31 versus 2/30 for the
titanium. Filter limb fracture occurred only with the
SGF model. No relationship of this complication to
recurrent PE was found. One half of the failures
occurred in patients with at least 2 prior PE. There
was a statistically significant association between the
indication for filter placement and filter failure rate,
with 5 of 6 having recurrent PE as the primary indi-
cation (P = .007, c 2-test, with 5 df). These patients
may benefit from closer surveillance when they are at
risk for deep venous thrombosis, such as after
surgery or during periods of prolonged immobility.
Thromboembolism prophylaxis is especially impor-
tant for this group. 
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Table II. Clinically important outcomes stratified by type of filter
(n) SGF (n) TGF-SH (n) TGF-MH (n) PSGF (n) Total
Recurrent PE 4 1 1 0 6
Caval occlusion 2 0 1 1 4
Filter limb fracture 3 0 0 0 3
SGF, Stainless-steel Greenfield filter (original model); TGF-SH, titanium Greenfield filter with standard curved hooks (no longer made);
TGF-MH, modified-hook titanium Greenfield filter (current model); PSGF, percutaneous stainless-steel Greenfield filter (current model
for guidewire); PE, pulmonary embolism.
Table III. Suprarenal filter types and techniques
for insertion
Types and techniques No of filters placed
1 filter 127
2 filter 21*
Types of filters
Original stainless 65
Percutaneous stainless 22
Titanium 60
Route
Right femoral 38
Right jugular 54
Left femoral 11
Left jugular 5
Unspecified 40
Technique
Surgical 60
Percutaneous 88
Misplacements 6
Retrieval 1
*19 placed after problem with infrarenal filter.
Table IV. Follow-up characteristics of patients with
suprarenal filters
No of patients
Characteristics (n = 73)
Anticoagulation therapy 35 (48%)
Complications 5
Edema 55 (75%)
Support hose 29 (40%)
Ulceration 4
Insertion site patent 63
Caval occlusion
Early 4
Long term 2
Recurrent PE 6
New venous abnormality 1
Penetration
Suspected 4 (5%)
Confirmed 1 (1%)
Migration
Cephalad 0
Caudad 11 (2-80 mm)
Mean follow-up (range) 81.6 months 
(0-278 months)
Mean follow-up visits 3.5
PE, pulmonary embolism.
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In addition to a filter, all patients underwent
anticoagulation therapy during the follow-up peri-
od. We were unable to support an association
between the use of anticoagulation therapy and the
recurrence of PE (P = 1.0, Fisher exact test, 1 df).
However, anticoagulation therapy should be used
when possible to treat underlying venous thrombo-
sis. We also failed to find an association between fil-
ter failure rate and survival rate (t test, P = .2, with
6 df). On average, the male patients in this group
were 15 years older than the female patients (57 vs
42 years, P = .0001). Male patients and female
patients were similar with respect to primary diag-
nosis and indication for filter placement. Male
patients who had SR filters were older and had
recurrent PE as an indication at a higher rate than
did female patients. This difference may be caused
by the tendency to place SR filters in female patients
simply to avoid the potential for damage to a gravid
uterus, which thus creates a group with a lower risk
of recurrence. Finally, there were no statistically sig-
nificant associations among filter symmetry, tilt, or
change in base diameter and recurrent PE.
DISCUSSION
The SR vena cava is an appropriate and a safe
position for placement of the Greenfield filter when
indicated by underlying factors. The most common
indications include vena caval thrombosis to or
above the level of the renal veins (Fig. 7) or throm-
bus within the renal veins, avoidance of uterine
compression against the filter during a current or
anticipated pregnancy, and propagating thrombus
on a previously placed filter. Any patient with an
infrarenal filter and recurrent PE should undergo
vena cavography to determine whether thrombus is
propagating off of the filter and whether the patient
is a candidate for an SR filter. This long-term follow-
up shows no renal dysfunction and comparable rates
of both recurrent PE (8% vs 4%; P > .05) and caval
occlusion (5%). 
On the basis of the data, it appears that when fil-
ters are placed above the renal veins, the outcomes
for patients are influenced by the diagnosis and indi-
cation for placement and the stability of the filter
with respect to caudal migration. The tendency for
caudal migration is probably related to greater
downward compression forces at this level by the
diaphragm and the caudate lobe of the liver.
Fig. 6. Two limbs of this SGF were fractured 2 years after
placement. Patient is alive and well without sequelae 11
years later.
Fig. 7. Patient with large thrombus in inferior vena cava.
A, Filter was placed in suprarenal vena cava to protect
against large thrombus (B).
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Dr Daniel F. Fischer, Jr (Chattanooga, Tenn). This
paper represents another of a long line of reports on the
Greenfield filter by Dr Lazar Greenfield. This paper is an
extension of two previous papers—one in 1982 and one in
1992—that showed safe placements of this filter in the
suprarenal position. According to the data collected in the
Greenfield database consisting of 1932 filters placed, 7.6%
of these filters have been placed in the suprarenal position.
This paper analyzes 49% of these 148 filters placed in this
position. Therefore, it is important to note that the con-
clusions from this study are really an extrapolation of only
half of the suprarenal filters placed. Despite this small
drawback and on the basis of my experience and the dis-
cusion of this paper with several members of this society, I
believe that Dr Greenfield’s conclusions are valid. He
reports that the incidence rate of long-term vena caval
occlusion was approximately 3%. There were no cases of
renal dysfunction. These findings are as good as, if not
better than, findings reported from infrarenal filter place-
ment. It would appear that the only limitation of
suprarenal placement is the finding that if the filter is
placed for recurrent pulmonary emboli on coumadin,
there is an 8% chance of continued embolization despite
optimum suprarenal placement.
I have three questions for Dr Greenfield.
First, you mention migration of these filters in 11
patients. However, there is no mention of cephalad migra-
tion, which I have personally seen in two patients. Have
the changes from regular hooks on the struts to reverse
hooks stopped cephalad migration altogether?
Second, if a physician chooses to place a filter in the
suprarenal position, what is the ideal level of placement?
Do the hepatic veins and diaphragmatic excursion affect
suprarenal placement at all?
Lastly, if any coagulation is not contraindicated, can
coumadin be stopped at 6 months without concern that
the cava might thrombose?
Although the indications for suprarenal placement are
rare, Dr Greenfield has reassured us, once again, that it
can be done safely. We must remember, however, that
recurrent embolization is still a possibility, especially if the
filter was placed for recurrent pulmonary emboli on
coumadin.
Thank you.
Dr Lazar J. Greenfield. Thank you, Dr Fisher. Your
first question related to the issue of migration and whether
or not hook geometry seems to influence that. We have
personally not seen any cephalad migration. I think that
the hook change, which produced a more obtuse angle, is
responsible for the stability of the device in both direc-
tions, as I mentioned. I think that the slippage we tended
to see, primarily in males who would have larger cavas and
also primarily with the original stainless steel device, is a
feature of the fact that device was secure only for an
upward direction and not as secure for forces wanting to
push it distally. As far as the level is concerned, we had a
great deal of concern about proximity to the hepatic veins,
but in long-term follow-up that has not seemed to be a
problem. In fact, we would advocate a somewhat higher
location in the suprarenal cava than trying to have it too
close to the renal veins, so that the T12 L1 level would
seem to be appropriate for these patients. And, as you can
see in the first x-ray that I showed, some of those thrombi
force you to place the filter at an even higher level. That
seems to be well tolerated, and we have not seen any
sequelae from it.
As far as anticoagulation therapy is concerned, the
same rules would apply that we have recommended for
infrarenal filters. That is, anticoagulation is appropriate for
maintaining control of the thrombus alone, and it is not
necessary for long-term patency of the filter. Whenever
you are satisfied that you have controlled the underlying
thrombotic disorder, anticoagulation therapy can be dis-
continued.
DISCUSSION
Placement should be high within the SR IVC,
given the potential for caudal migration and given
that the mechanical forces at this level seem to be
tolerated better by the titanium filter than the orig-
inal SGF. 
CONCLUSION
SR filter placement is a safe, effective method of
protection for those patients with extensive caval
thrombosis or a failed infrarenal filter or for female
patients of child-bearing potential. In this study, the
positioning the filter above the renal vein was not
associated statistically with increased morbidity or
mortality rates, even among patients who were the
most highly thrombogenic.
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